Drug intelligence / Profile preview

P1048

Development stage: Preclinical
Lead developer: Guerbet
Modality: Nanoparticles → Drug Delivery Systems
Administration: Injection

Overview

P1048 is an iron-oxide, folate-receptor-targeted contrast agent developed by Guerbet for magnetic resonance (MR) imaging of tumors, particularly ovarian tumors. It is designed to leverage the overexpression of the folate receptor (FR) in many human cancers to provide tumor-specific imaging capabilities. Preclinical studies have investigated its uptake and specificity in FR-positive ovarian cancer cells and implanted ovarian tumors in rat models.

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on P1048.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P1048.

Explore the full profile